International Clinical Trial: An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects with Recurrent or Progressive Grade 4 Glioma

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119774) titled 'An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects with Recurrent or Progressive Grade 4 Glioma' on March 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shanghai Tongji Hospital

Condition: Grade 4 Glioma

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-03

Target Sample Size: Experimental group:21;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=307623

D...